Skip to main content
Clinical Trials/CTRI/2024/09/074164
CTRI/2024/09/074164Not yet recruitingNot Applicable

To evaluate the irritation potential on healthy human subjects of Skin Care Formulation

G.D. Pharmaceuticals Pvt. Ltd.1 site in 1 country26 target enrollmentStarted: September 27, 2024Last updated:
Conditions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Sponsor
Enrollment
26
Locations
1
Primary Endpoint
Dermatological safety / Irritation potential on skin

Study Overview

Brief Summary

Objective: The objective of this study will be to evaluate the irritation potential on healthy human subjects of Skin Care Formulation

Duration of study: 8 days study

Kinetics: T0 (Evaluation of test sites by Dermatologist, Patch application) ,T1(Patch removal, Evaluation of test sites by Dermatologist ,T2(Evaluation of test sites by Dermatologist and Subject post 24 hrs of patch removal), T8 (Evaluation of test sites by Dermat and Subject post 1 week of patch removal and tracking the positive cases)

Population: 26 healthy subjects (13 males + 13 females) with varied skin types.

The test area is checked for erythema and oedema caused due to the products and compared with positive control

Study Design

Study Type
Interventional
Allocation
Na
Masking
None

Eligibility Criteria

Ages
18.00 Year(s) to 65.00 Year(s) (—)
Sex
All

Inclusion Criteria

  • •Healthy Human Subjects 2) Skin should be healthy on the studied anatomic unit (free of eczema, wounds, inflammatory scar….).
  • •Subjects willing to come for regular follow up and ready to follow instructions during the study period.

Exclusion Criteria

  • •1 For female: Being pregnant or breastfeeding or having stopped to breastfeed in the past three months 2 Having refused to give his/her assent by not signing the consent form 3 Taking part in another study liable to interfere with this study 4 Being diabetic.
  • •5 Being asthmatic.
  • •6 Following a chronic medicinal treatment comprising any of the following products: aspirin-based products, anti-inflammatories, antihistamines, corticotherapy, taken by general or local routes (the only medication permitted is paracetamol).
  • •7 Having cutaneous hypersensitivity (except in the case of studies with evaluation of sensitive skin).
  • •8 Having a diagnosed or highly probable allergy to one or several compounds of the cosmetic products.
  • •9 Having undergone a surgery requiring a general anaesthesia of more than one hour in the past 6 months.
  • •10 Having changed his/her cosmetic habits in the 14 days preceding the start of the study on the studied anatomic unit.

Outcomes

Primary Outcomes

Dermatological safety / Irritation potential on skin

Time Frame: Baseline,0 hrs,24 hrs and 7 days

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
G.D. Pharmaceuticals Pvt. Ltd.
Sponsor Class
Other [Fast-Moving Consumer Goods]
Responsible Party
Principal Investigator
Principal Investigator

Dr Pooja Yadav

MASCOT-SPINCONTROL India Pvt. Ltd.

Study Sites (1)

Loading locations...

Similar Trials